
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For the Month of April, 2014

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_____.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: April 17, 2014

By: /s/ "Elizabeth Williams"
Elizabeth Williams
Director of Finance and Controller

EXHIBIT INDEX

- 99.1 Lorus Therapeutics Announces the Departure of its President and Chief Operating Officer
- 99.2 Lorus Therapeutics Inc. Announces \$17M Overnight Marketed Financing
- 99.3 Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to \$25M
- 99.4 Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014
- 99.5 Lorus Therapeutics Presents Preclinical Data on LOR-253 at American Association for Cancer Research Annual Meeting 2014
- 99.6 Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast
- 99.7 Lorus Therapeutics Completes \$25 Million Offering of Common Shares
- 99.8 Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014



**Lorus Therapeutics Announces the Departure of its
President and Chief Operating Officer**

TORONTO, ONTARIO - March 18, 2014 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”) announced that Dr. Aiping Young is leaving her position as President and Chief Operating Officer of Lorus, effective today. William G. Rice, Ph.D., Chairman of the Board and Chief Executive Officer of the Company, and the other members of the Company’s Board of Directors, on behalf of Lorus, thank Dr. Young for her years of service to the Company and wish her well in her future endeavors. Dr. Young’s responsibilities will be assumed by other members of senior management.

About Lorus

Lorus is a biopharmaceutical company targeting essential apoptosis pathways to deliver transformational cancer drugs. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used alone and in combination with other drugs to successfully treat specific forms of cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and US securities laws. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

###

Enquiries:

For further information, please contact:

Greg Chow, Chief Financial Officer

416-798-1200

gchow@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com



THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

LORUS THERAPEUTICS INC. ANNOUNCES \$17M OVERNIGHT MARKETED FINANCING

Toronto, Ontario, March, 26, 2014 - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company") announces that it has filed a preliminary short form prospectus in connection with an overnight marketed public offering (the "Offering") of common shares of the Company (the "Common Shares") for approximately \$17 million. The Offering will be conducted through a syndicate of underwriters led by RBC Capital Markets and including Roth Capital Partners and Cormark Securities Inc. (the "Underwriters"). The Company has agreed to grant to the Underwriters an over-allotment option to purchase that number of additional Common Shares equal to 15% of the Common Shares sold pursuant to the Offering at the offering price for a period ending 30 days following the closing of the Offering. The definitive price of the Offering will be determined in the context of the market with the final terms to be agreed upon at the time of the entering into of an underwriting agreement.

The net proceeds from the Offering will be used to develop the Company's lead clinical agent LOR-253, fund related clinical trials in Acute Myeloid Leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies, fund the Company's manufacturing program, support ongoing research and development programs and for general and corporate working capital purposes.

The Common Shares will be offered in all of the provinces of Canada, excluding Quebec, by way of short form prospectus, and may also be offered in other jurisdictions in a manner permitted by applicable securities laws.

The Offering is expected to close on or about April 10, 2014, subject to customary conditions and all regulatory approvals including the approval of the Toronto Stock Exchange and of applicable securities regulatory authorities and the entering into of an underwriting agreement between the Company and the Underwriters.

The securities being offered have not been, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered, sold or delivered, directly or indirectly, within the United States absent U.S. registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Lorus

Lorus is a clinical stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:
Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com



THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

LORUS THERAPEUTICS INC. UPSIZES OVERNIGHT MARKETED FINANCING TO \$25M

Toronto, Ontario, March 27, 2014 - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company") is pleased to announce that, in connection with its previously announced overnight marketed public offering (the "Offering"), it has entered today into an underwriting agreement with a syndicate of underwriters led by RBC Capital Markets and including Roth Capital Partners and Cormark Securities Inc. (collectively, the "Underwriters") to sell 50,000,000 common shares of the Company (the "Common Shares") at a price of \$0.50 per Common Share (the "Offering Price"), for aggregate gross proceeds of \$25,000,000. In addition, the Company has granted to the Underwriters an over-allotment option to purchase up to 7,500,000 additional Common Shares at the Offering Price (the "Over-Allotment Option"). The Over-Allotment Option may be exercised at any time up to 30 days following the closing of the Offering.

The net proceeds from the Offering will be used to develop the Company's lead clinical agent LOR-253, fund related clinical trials in Acute Myeloid Leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies, fund the Company's manufacturing program, support ongoing research and development programs and for general and corporate working capital purposes.

The Common Shares will be offered in all of the provinces of Canada, excluding Quebec, by way of short form prospectus, and may also be offered in other jurisdictions in a manner permitted by applicable securities laws.

The Offering is expected to close on or about April 10, 2014, subject to customary conditions and all regulatory approvals including the approval of the Toronto Stock Exchange and of applicable securities regulatory authorities.

The securities being offered have not been, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered, sold or delivered, directly or indirectly, within the United States absent U.S. registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Lorus

Lorus is a clinical stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:
Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com



Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014

TORONTO, CANADA - April 4, 2014 - Lorus Therapeutics Inc. (TSX: LOR) today announced it will present preclinical data for LOR-253 in acute myeloid leukemia (AML) and other hematologic cancers at the American Association for Cancer Research (AACR) Annual Meeting 2014, to be held at the San Diego Convention Center in San Diego, CA, April 5-9, 2014.

LOR-253, the company's lead anti-cancer agent, is a clinical-stage, small molecule therapeutic that acts through induction of the innate tumor suppressor Krüppel-like factor 4 (KLF4). Lorus is currently pursuing the clinical development of LOR-253 in AML based on recent research that has implicated up-regulation of various transcription factors, including CDX2, as a causative gene in the development or progression of leukemic disease. The CDX2 protein has been shown to silence the KLF4 tumor suppressor gene, reported to be a critical oncogenic event in AML. LOR-253 is the only clinical-stage agent to act through the induction of KLF4 and may represent a novel approach for the treatment of AML and other hematologic malignancies.

In a prior single-agent, Phase I clinical study, LOR-253 demonstrated antitumor activity and a robust safety profile in patients with solid tumors.

At the 2014 AACR meeting, Lorus researchers will present preclinical data on the effect of LOR-253 in acute myeloid leukemia and other blood cancer cell lines:

Poster presentation: ***Induction of KLF4 by LOR-253 as an innovative therapeutic approach to induce apoptosis in acute myeloid leukemia***

- Tuesday, April 08, 2014, 1:00 PM - 5:00 PM PDT
- Location: Hall A-E, Poster Section 31, Poster Board #3
- Abstract #4544

About Lorus

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Lorus Therapeutics

Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com



Lorus Therapeutics Presents Preclinical Data on LOR-253 at American Association for Cancer Research Annual Meeting 2014

TORONTO, CANADA - April 8, 2014 - Lorus Therapeutics Inc. (TSX: LOR) today announced the presentation of preclinical data for LOR-253, the company's lead anti-cancer agent, at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, CA. Lorus researchers demonstrated the ability of LOR-253 to induce cell death, or apoptosis, in blood cancer cell lines, including Acute Myeloid Leukemia (AML) cells, *in vitro* and concluded that the studies support further evaluation of LOR-253 as a potential therapy for AML and other hematologic cancers.

LOR-253 is a clinical-stage, small molecule therapeutic that acts through induction of the innate tumor suppressor Krüppel-like factor 4 (KLF4). Lorus is currently pursuing the clinical development of LOR-253 in AML based on recent research that has implicated up-regulation of various transcription factors, including CDX2, as a causative gene in the development or progression of leukemic disease. The CDX2 protein has been shown to silence the KLF4 tumor suppressor gene, which is reported to be a critical oncogenic event in AML.

Today, Dr. Yoon Lee, Lorus' Senior Vice President of Research, presented data demonstrating that LOR-253 exerts anti-proliferative activity against various human leukemia and lymphoma cell lines *in vitro* with low nM IC₅₀ potency. Further, LOR-253 induces KLF4 mRNA expression in AML cells, resulting in an increase in the expression of p21, a cyclin-dependent kinase inhibitor that is transcriptionally regulated by KLF4. Consistent with these results, LOR-253 was found to induce cell cycle arrest and apoptosis, demonstrating that LOR-253 acted through its intended mechanism of action to kill AML cell lines. LOR-253 also showed strong anti-cancer synergy when used in combination with conventional chemotherapeutics (e.g., daunorubicin, azacitidine, decitabine and cytarabine) used to treat patients with certain hematologic malignancies. With the potential to reactivate the silenced KLF4 gene and induce apoptosis in AML, LOR-253 may offer an important new approach for the treatment of AML and possibly other hematologic malignancies.

Studies are underway to further characterize the pathway that mediates KLF4 induction by LOR-253, to characterize the effects of LOR-253 in combination with approved chemotherapies for AML, and to assess the efficacy of LOR-253 in animal models of AML. In a prior single-agent Phase I clinical study, LOR-253 demonstrated antitumor activity and a robust safety profile in patients with solid tumors. A dose-escalating Phase 1b trial, evaluating safety and efficacy as a monotherapy in AML, MDS and other hematologic malignancies, is anticipated to begin during the summer of 2014.

About Lorus

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Lorus Therapeutics

Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com



Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast

TORONTO, CANADA - April 8, 2014 - Lorus Therapeutics Inc. (TSX: LOR) today announced it intends to release financial results for the quarter ended February 28, 2014, on Thursday, April 10, 2014 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. EDT to discuss the financial results.

Participants can access the conference call by dialing 1-888-231-8191 (North American toll free number) or 647-427-7450 (local). The conference call will be available via a live webcast at <http://www.newswire.ca/en/webcast/detail/1335393/1476021>, and will also be available through a link on the Investor Relations section of Lorus' website at <http://www.lorusthera.com/investors/index.php>. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast will be available on the company's website for 30 days. An audio replay of the webcast will be available approximately two hours after the conclusion of the call for 30 days by dialing 1-855-859-2056, using the passcode 27043239.

The press release, the financial statements and the management's discussion and analysis for the quarter ended February 28, 2014 will be available on SEDAR at www.sedar.com.

About Lorus

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Lorus Therapeutics

Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com



THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

LORUS THERAPEUTICS INC. COMPLETES \$25 MILLION OFFERING OF COMMON SHARES

Toronto, Ontario, April 10, 2014 - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus") is pleased to announce that it has completed today its previously announced public offering (the "Offering") of common shares of Lorus (the "Offered Shares").

Lorus issued a total of 50,000,000 Offered Shares at a price of \$0.50 per Offered share (the "Offering Price") for aggregate gross proceeds of \$25,000,000. The Offering was sold to a syndicate of underwriters led by RBC Capital Markets and including Roth Capital Partners and Cormark Securities Inc. (collectively, the "Underwriters") upon the terms of an underwriting agreement entered into among Lorus and the Underwriters. In addition, Lorus has granted to the Underwriters an over-allotment option to purchase up to 7,500,000 additional Common Shares at the Offering Price (the "Over-Allotment Option") for a period ending 30 days following the closing of the Offering.

"We are pleased to have received strong support from our current and new investors, representing prominent global and US healthcare investment funds and Canadian institutional investors," said William G. Rice, PhD, Chairman and Chief Executive Officer of Lorus. "We are confident that the proceeds from this Offering will allow us to make important advances in the clinical development and manufacturing scale-up of our lead program, LOR-253, which may have potential to become an important new anticancer therapeutic in AML and other hematologic cancers."

Mr. Sheldon Inwentash, exercising control or direction over more than 10% of the common shares of Lorus prior to the Offering, participated in the Offering and acquired, through Pinetree Capital Ltd., an aggregate of 1,300,000 Offered Shares. After the close of the Offering, Mr. Inwentash and his joint actors, collectively hold 9,220,000 common shares of Lorus (8.2% of the issued and outstanding common shares of Lorus), 4,750,000 common share purchase warrants and convertible promissory notes in the amount of \$150,000, convertible, at a conversion price of \$0.30 per common share, into a maximum of 500,000 common shares of Lorus. If Mr. Inwentash and his joint actors were to exercise all of the warrants and convert all the convertible promissory notes controlled by them, they would hold 14,470,000 common shares of Lorus (12.31% of the issued and outstanding common shares of Lorus on a partially diluted basis). The participation of Mr. Inwentash and his joint actors in the Offering constitutes a "related party transaction" as defined under *Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions* ("MI 61-101"). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to insiders nor the consideration being paid by insiders will exceed 25% of Lorus' market capitalization. Lorus did not file a material change report 21 days prior to the closing of the Offering as the details of the participation of insiders of Lorus had not been confirmed at that time.

The net proceeds from the Offering will be used to fund Lorus' manufacturing program of LOR-253, support ongoing research and development programs, fund potential single agent expansion and drug combination Phase 2 trials in both Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS) patients (depending on Phase 1b clinical trial of LOR-253 results) and for general and corporate working capital purposes.

The Offered Shares were distributed under a short form prospectus dated April 4, 2013 and details of the distribution are set out in the short form prospectus which is available on SEDAR at www.sedar.com.

About Lorus

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to Lorus' plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:
Greg Chow, Chief Financial Officer
416-798-1200
gchow@lorusthera.com



NEWS RELEASE

Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014

TORONTO, CANADA - April 10, 2014 - Lorus Therapeutics Inc. (TSX: LOR) (Lorus") reported financial results for the three and nine months ended February 28, 2014 and provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.

The net loss for the quarter ending February 28, 2014 was \$2.4 million, or (\$0.04) per share, compared with a net loss of \$1.4 million, or (\$0.03) per share, for the same period in the prior year. Total cash and cash equivalents as of February 28, 2014 totaled \$7.2 million.

"In the third quarter and recent weeks we made significant progress in raising capital that will support the clinical development advancement of Lorus lead agent LOR-253 in hematologic cancers," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "With the closing of a \$25 million financing announced today, we expect to have the capital needed to execute our developmental milestones for the foreseeable future."

THIRD QUARTER 2014 AND RECENT HIGHLIGHTS

Corporate Highlights

- On April 10, 2014, Lorus announced the closing of a public offering of common shares raising gross proceeds of \$25 million. As part of the offering Lorus issued 50,000,000 common shares at a price of \$0.50 per share.
- On April 10, 2014, the Board of Directors appointed William G. Rice, Ph.D., as President of Lorus, in addition to his position of Chief Executive Officer and Chairman and Avanish Vellanki and Gregory K. Chow as Senior Vice Presidents, in addition to their respective position of Chief Business Officer and Chief Financial Officer, following the departure of Aiping Young, Ph.D., former President and Chief Operating Officer of Lorus.
- On April 8, 2014, Lorus presented preclinical data on LOR-253 at the American Association for Cancer Research Annual Meeting 2014.
- On January 8, 2014, the underwriters in the December 2013 public offering exercised in full their over-allotment to purchase an additional 1,909,500 common shares of Lorus at a price of \$0.55 per share for additional gross proceeds of \$1.05 million.
- On December 10, 2013, Lorus completed a public offering of common shares. Lorus issued a total of 12,730,000 common shares at a price of \$0.55 per common share for aggregate gross proceeds of \$7.0 million.
- On December 2, 2013, Avanish Vellanki was appointed Chief Business Officer overseeing global business development, licensing and corporate strategy, and Gregory K. Chow was appointed Chief Financial Officer with responsibility for corporate finance and accounting functions.

LOR-253 Update at AACR Annual Meeting

- On April 8, 2014, Lorus presented preclinical data for LOR-253, Lorus' lead anti-cancer agent, at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, CA. Lorus researchers demonstrated the ability of LOR-253 to induce cell death, or apoptosis, in blood cancer cell lines, including Acute Myeloid Leukemia (AML) cells, *in vitro* and concluded that the studies support further evaluation of LOR-253 as a potential therapy for AML and other hematologic cancers.
- LOR-253 also showed strong anti-cancer synergy when used in combination with conventional chemotherapeutics (e.g., daunorubicin, azacitidine, decitabine and cytarabine) used to treat patients with certain hematologic malignancies. With the potential to reactivate the silenced KLF4 gene and induce apoptosis in AML, LOR-253 may offer an important new approach for the treatment of AML and possibly other hematologic malignancies.

FINANCIAL RESULTS

Our net loss for the three months ended February 28, 2014 was \$2.4 million (\$0.04 per share) compared to \$1.4 million (\$0.03 per share) in the same period in the prior year. Lorus incurred a net loss of \$6.3 million (\$0.13 per share) for the nine months ended February 28, 2014 compared to \$4.2 million (\$0.10 per share) during the same period in the prior year.

In the three-month period ended February 28, 2014 research and development expenditures decreased by \$292,000 due to reduced spending on our LOR-253 program as the Phase I clinical trial was completed and additional clinical studies were postponed until adequate financing was secured. In addition, no further expenses on the IL-17E development program were incurred in the three months ended February 28, 2014, compared with \$118,000 in the same period in the prior year. The reduction in program expenditures was offset by increased deferred share unit costs due to an increase in their fair value associated with an increased share price. General and administrative expenses increased \$1.3 million in the three months ended February 28, 2014 compared with the prior year due to increased stock-based compensation, deferred share unit and salary costs associated with engaging new executives and an increase in our share price during the quarter as well as additional travel, legal and consulting costs.

In the nine-month period ended February 28, 2014 research and development expenditures decreased by \$454,000 due to reduced program activity in the current year as the Phase I clinical trial completed and future development and expenditures were paused, offset by higher stock based compensation and deferred share unit costs. General and administrative expenses increased by \$2.3 million in the nine months ended February 28, 2014 compared with the prior year due primarily to increased stock based compensation, deferred share unit and salary costs associated with engaging new executives and an increase in our share price during the nine-month period ended February 28, 2014.

We utilized \$2.2 million in cash for operating activities in three-month period ended February 28, 2014 compared with \$1.3 million during the same period the prior year. For the nine months ended February 28, 2014 we utilized cash of \$4.6 million compared with \$4.2 million in the same period last year. The increase in cash utilized in the three and nine months ended February 28, 2014 is due to increased net loss due to increased general and administrative activities associated with the hiring of three senior management executives and significantly increased corporate activities described above.

At February 28, 2014, Lorus had cash and cash equivalents of \$7.2 million compared to \$653,000 at May 31, 2013. Subsequent to the quarter end on February 28, 2014, Lorus raised gross proceeds of approximately \$25 million through a public offering of its common shares.

For further details and to view Lorus' May 31, 2013 Audited Consolidated Financial Statements and Management's Discussion and Analysis, please see Lorus' filings on www.sedar.com and on www.lorusthera.com.

Lorus Therapeutics Inc.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(unaudited)

(amounts in 000's of Canadian Dollars except for per common share data)

	Three months ended Feb 28, 2014	Three months ended Feb 28, 2013	Nine months ended Feb 28, 2014	Nine months ended Feb 28, 2013
REVENUE	\$ —	\$ —	\$ —	\$ —
EXPENSES				
Research and development	597	889	2,003	2,457
General and administrative	1,771	491	4,160	1,812
Operating expenses	2,368	1,380	6,163	4,269
Finance expense	78	—	184	6
Finance income	(13)	(9)	(15)	(26)
Net financing expense (income)	65	(9)	169	(20)
Net loss and total comprehensive loss for the period	2,433	1,371	6,332	4,249
Basic and diluted loss per common share	\$ 0.04	\$ 0.03	\$ 0.13	\$ 0.10

Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000's)	61,271	42,251	49,085	42,251
----------------------------------------------------------------------------------------------------------------------------------------	--------	--------	--------	--------

CONFERENCE CALL AND WEBCAST

Lorus will host a conference call to discuss results for the quarter ended February 28, 2014 on Thursday, April 10, 2014 at 5:00 p.m. EDT. Participants can access the conference call by dialing 1-888-231-8191 (North American toll free number) or 647-427-7450 (local). The conference call will be available via a live webcast at <http://www.newswire.ca/en/webcast/detail/1335393/1476021>, and will also available through a link on the Investor Relations section of Lorus' website at <http://www.lorusthera.com/investors/index.php>. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast will be available on the Company's website for 30 days. An audio replay of the webcast will be available approximately two hours after the conclusion of the call for 30 days by dialing 1-855-859-2056, using the passcode 27043239.

NOTE

The information contained in this news release is unaudited.

About Lorus

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our ability to obtain financing or partnerships, the establishment of corporate alliances, our ability to maintain current and future corporate alliances, our ability to fund or reach developmental milestones, Lorus' plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Lorus Therapeutics

Greg Chow, CFO
416-798-1200
gchow@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com